On 30 September, the Guangdong Medical Products Administration officially issued newly revised implementation rules for the inspection and acceptance of pharmaceutical retail licences in the province. The rules took effect on 1 October and will remain valid for five years.

On 20 September, the National Medical Products Administration (NMPA) released a plan to optimise the review and approval procedures for supplementary applications relating to traditional Chinese medicines (TCM). This reform plan applies to supplementary applications for pharmaceutical changes to TCM products and revisions to safety information in package inserts, excluding TCM injections. Measures will be implemented in qualifying provincial drug regulatory departments.

The U.S. Drug Enforcement Administration is proposing to adopt import restrictions on certain additional hallucinogens.

The Bureau of Industry and Security recently issued a notice defining the pharmaceutical products and listing the jurisdictions eligible to receive a zero Section 232 tariff rate.